Pacira Pharmaceuticals (PCRX) PT Raised to $31 at Truist Securities
October 7, 2026 7:14 AM
Truist Securities analyst Anish Nikhanj raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $31.00 (from $30.00) while maintaining a Buy rating.
